Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R; EORTC Quality of Life Group. Postma TJ, et al. Among authors: huddart r. Eur J Cancer. 2005 May;41(8):1135-9. doi: 10.1016/j.ejca.2005.02.012. Epub 2005 Apr 14. Eur J Cancer. 2005. PMID: 15911236
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma.
Loriot Y, Sternberg CN, Castellano D, Oosting SF, Dumez H, Huddart R, Vianna K, Alonso Gordoa T, Skoneczna I, Fay AP, Nolè F, Massari F, Brasiuniene B, Maroto P, Fear S, Di Nucci F, de Ducla S, Choy E. Loriot Y, et al. Among authors: huddart r. Eur J Cancer. 2020 Oct;138:202-211. doi: 10.1016/j.ejca.2020.07.023. Epub 2020 Sep 6. Eur J Cancer. 2020. PMID: 32905959 Clinical Trial.
The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011).
Moynihan C, Lewis R, Hall E, Jones E, Birtle A, Huddart R; SPARE Trial Management Group. Moynihan C, et al. Among authors: huddart r. Trials. 2012 Nov 29;13:228. doi: 10.1186/1745-6215-13-228. Trials. 2012. PMID: 23190503 Free PMC article. Clinical Trial.
Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.
Zhang X, Trendowski MR, Wilkinson E, Shahbazi M, Dinh PC, Shuey MM; Regeneron Genetics Center; Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Huddart R, Martin NE, Sanchez VA, Frisina RD, Einhorn LH, Cox NJ, Travis LB, Dolan ME. Zhang X, et al. Among authors: huddart r. Cancer Med. 2022 Jul;11(14):2801-2816. doi: 10.1002/cam4.4644. Epub 2022 Mar 23. Cancer Med. 2022. PMID: 35322580 Free PMC article.
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, Ellis M, Moody R, Stanton L, Galanopoulou A, Maishman T, Geldart T, Bayne M, Davies J, Lamb C, Popat S, Joffe JK, Nutting C, Chester J, Hartley A, Thomas G, Ottensmeier C, Huddart R, King E. Crabb SJ, et al. Among authors: huddart r. Eur J Cancer. 2017 Dec;87:75-83. doi: 10.1016/j.ejca.2017.09.033. Epub 2017 Nov 10. Eur J Cancer. 2017. PMID: 29128692 Free PMC article. Clinical Trial.
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A; Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Cullen M, et al. Among authors: huddart r. N Engl J Med. 2005 Sep 8;353(10):988-98. doi: 10.1056/NEJMoa050078. N Engl J Med. 2005. PMID: 16148284 Free article. Clinical Trial.
378 results